Search results
Results from the WOW.Com Content Network
Men without prostate cancer typically have PSA levels of under 4 nanograms per milliliter (ng/mL), according to the American Cancer Society. PSA levels between 4 and 10 suggest you could have ...
Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), P-30 antigen, is a glycoprotein enzyme encoded in humans by the KLK3 gene.PSA is a member of the kallikrein-related peptidase family and is secreted by the epithelial cells of the prostate gland in men and the paraurethral glands in women.
Prostate cancer screening is the screening process used to detect undiagnosed prostate cancer in men without signs or symptoms. [1] [2] When abnormal prostate tissue or cancer is found early, it may be easier to treat and cure, but it is unclear if early detection reduces mortality rates.
In a separate study of men from the pre prostate cancer screening era managed with watchful waiting (56% over age 70 years), progression to distant metastasis or prostate cancer death was 13.9% and 12.3%, respectively for Gleason score 6 or below, but considerably higher at 18.2 and 22.7%, 30% and 20%, 44.4% and 55.6% for Gleason 3+4, 4+3, and ...
Men with PSA levels above 4 ng/mL are at increased risk – around 1 in 4 will develop prostate cancer – and are often referred for a prostate biopsy. [15] [16] PSA levels over 10 ng/mL indicate an even higher risk: over half of men in this group develop prostate cancer. [15]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.
Richard J. Ablin was an American scientist, most notable for research on prostate cancer.According to the Wall Street Journal: . Richard Ablin, a professor of pathology at University of Arizona College of Medicine, discovered the prostate-specific antigen (PSA) in 1970, and for nearly as long, he has argued that it should not be used for routine screening.